Overall rank by patents
#41,496
Across all tracked assignees
USPTO PatentsView assignee record - 6 granted patents across 10 technology areas, active 2017–2021. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
The verdict
Luye holds 6 US patents across 10 technology areas, rank #41,496 of 50,000 tracked assignees.
Luye Pharma Ag has been granted 6 US utility patents between 2017 and 2021, placing Luye Pharma Ag at rank #41,496 across all assignees tracked by PlainPatent. This portfolio spans 10 distinct Cooperative Patent Classification (CPC) subclasses, averaging 22.2 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, Luye Pharma Ag is one of the more focused assignees in the PatentsView dataset. By volume, Luye sits between Lunatec (6 patents, rank #41,492) and Machine Vision Lighting Inc. (6 patents, rank #41,500) - the closest US assignees by grant volume. The composite Innovation Score of 31.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 4 grants, compared with 2 in the 2015–2019 window, a +100% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Luye Pharma Ag's 22.2 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 10 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Luye Pharma Ag against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Lunatec
6 patents
Lunghwa University of Science and Technology
6 patents
Luno, Inc.
6 patents
LuxTech, LLC
6 patents
Lystek International Corp.
6 patents
M. ALPHABET 3, LLC
6 patents
M. I. Co., Ltd.
6 patents
MACHINE VISION LIGHTING INC.
6 patents
Luye Pharma AG
6 patents
What this shows Luye holds 6 patents at rank #41,496, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #41,496 in granted patent volume.
Other assignees with the most granted patents in Luye's primary technology class.
Luye's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
31 Top 63% higher than 37% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 1 | 16.7% |
| 2018 | 1 | 16.7% |
| 2020 | 3 | 50.0% |
| 2021 | 1 | 16.7% |
Top 10 of 10 technology areas
Overall rank by patents
#41,496
Across all tracked assignees
31.2 out of 100
How to use this portfolio
Luye's 6 grants land it in the top 63% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.